Reductions in Absolute PASI Over 144 Weeks of Treatment with Certolizumab Pegol in Patients with Plaque Psoriasis: Pooled Analysis from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)

Main Article Content

AB Gottlieb
Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY

A Blauvelt
Oregon Medical Research Center, Portland, OR

D Tha?i
Institute and Comprehensive Center for Inflammation Medicine, University of L?beck, L?beck, Germany

Y Poulin
Centre de Recherche Dermatologique du Qu?bec M?tropolitain, Qu?bec, Canada

F Brock
UCB Pharma, Slough, UK

C Arendt
UCB Pharma, Brussels, Belgium

M Boehnlein
UCB Pharma, Monheim am Rhein, Germany

K Reich
Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf and Skinflammation? Center, Hamburg, Germany

Keywords

Psoriasis, Plaque Psoriasis, Biologic, Tumor Necrosis Factor α, TNF α, Certolizumab Pegol

Abstract

Abstract not available.

References

1. Parisi R. J Invest Dermatol 2013;133:377–85

2. Gottlieb AB. JAAD 2018;79:302–14

3. Lebwohl M. JAAD 2018;79:266–76

4. Zweegers J. et al. Br J Dermatol 2017;176:786–93

5. Carrascosa Carrillo JM. J Dermatolog Treat 2017;29:140–4

6. Puig L. Eur J Dermatol 2015;25:410–7.

Article Sidebar

Poster PDF
Published
Oct 27, 2020
DOI https://doi.org/10.25251/skin.4.supp.84

Article Details

How to Cite
[1]
Gottlieb, A., Blauvelt, A., Tha?i, D., Poulin, Y., Brock, F., Arendt, C., Boehnlein, M. and Reich, K. 2020. Reductions in Absolute PASI Over 144 Weeks of Treatment with Certolizumab Pegol in Patients with Plaque Psoriasis: Pooled Analysis from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2). SKIN The Journal of Cutaneous Medicine. 4, 6 (Oct. 2020), s84. DOI:https://doi.org/10.25251/skin.4.supp.84.
Issue
Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Section
Poster Presentations from FC20 Clinical Dermatology Conference®: Psoriasis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 4 > >>